Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of $75.0 million of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional $11.25 million of its common stock